Omnicell (OMCL)
(Delayed Data from NSDQ)
$40.85 USD
+0.65 (1.62%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $40.87 +0.02 (0.05%) 6:24 PM ET
4-Sell of 5 4
C Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OMCL 40.85 +0.65(1.62%)
Will OMCL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for OMCL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OMCL
Omnicell (OMCL) Q2 Earnings Top Estimates, Margins Down
Omnicell (OMCL) Surpasses Q2 Earnings and Revenue Estimates
OMCL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Hims & Hers Health, Inc. (HIMS) Earnings Expected to Grow: Should You Buy?
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
Omnicell (OMCL) Banks on Product Launches, Global Growth
Other News for OMCL
The 1-Minute Market Report August 3, 2024
Omnicell, Inc. (OMCL) Q2 2024 Earnings Call Transcript
Omnicell upgraded at Barclays after earnings-driven rally
Omnicell price target raised by $10 at BofA, here's why
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Alnylam Pharma (ALNY) and Omnicell (OMCL)